M Ventures invests in innovative technologies and products with the potential to significantly impact Merck‘s core business areas.
Business Model:
Revenue: $0
Employees: 0-0
Address: Gustav Mahlerplein 102 Toyo lto Building
City: Amsterdam
State: noord-holland
Zip: 1082 MA
Country: NL
Merck Ventures is the strategic, corporate venture capital arm of Merck. Its mandate is to invest in innovative technologies and products with the potential to significantly impact Merck‘s core business areas. From its headquarters in Amsterdam and offices in the US and Israel we invest globally in transformational ideas driven by great entrepreneurs. Merck Ventures takes an active role in its portfolio companies and teams up with entrepreneurs and co-investors to translate innovation towards commercial success. Merck Ventures has a significant focus on early-stage investing and company creation including the creation of spin-offs to leverage Merck‘s science and technology base.
Contact Phone:
Contact Email:
Announced Date | Company | Transaction | Money Raised |
---|---|---|---|
1/2012 | Translate Bio | Series A | 20.7M |
10/2021 | DNA Script | Series C | 0 |
7/2016 | Akili Interactive Labs | Series B | 42.4M |
10/2017 | aveni | Series B | 10.5M |
2/2022 | Celestial AI | Series A | 56M |
7/2018 | Mosa Meat | Series A | 0 |
3/2022 | Concerto Biosciences | Series A | 24.5M |
12/2019 | Neurable | Series A | 6M |
7/2015 | Translate Bio | Series B | 0 |
6/2018 | Mighty Bear Games | Seed Round | 2.5M |
11/2018 | Ribometrix | Series A | 30M |
4/2011 | F-Star Therapeutics | Venture Round | 0 |
1/2021 | Theolytics | Series A | 6.8M |
10/2014 | Forendo Pharma | Series A | 0 |
6/2018 | Inthera Bioscience | Series A | 0 |
10/2022 | Nucleome Therapeutics | Series A | 42.3M |
9/2020 | Tipe | Seed Round | 2.1M |
3/2023 | PxE | Seed Round | 0 |
11/2017 | Biolinq | Series A | 0 |
2/2022 | Micropsi Industries | Series B | 0 |
3/2019 | Biolinq | Series A | 4.8M |
5/2009 | Bird Rock Bio | Series A | 13M |
6/2020 | Micropsi Industries | Series A | - |
10/2013 | F-Star Therapeutics | Series A | 0 |
5/2021 | Soteria Biotherapeutics | Series A | 42M |
1/2018 | Rewind Therapeutics | Series A | 18.3M |
1/2010 | F-Star Therapeutics | Series A | 11.5M |
4/2020 | FoRx Therapeutics | Seed Round | 10.8M |
4/2016 | Metabomed | Series A | 18M |
10/2014 | Raze Therapeutics | Series A | 24M |
1/2023 | Rewind Therapeutics | Series A | - |
2/2020 | Scipio Bioscience | Series A | 6.5M |
6/2016 | Storm Therapeutics | Series A | 16M |
9/2020 | SeeQC | Series A | 22.4M |
7/2019 | SIMULATE | Seed Round | 7M |
3/2022 | Altoida | Series A | 0 |
9/2018 | Forendo Pharma | Venture Round | 0 |
5/2017 | Inthera Bioscience | Series A | 0 |
3/2020 | Xilio Therapeutics | Series B | 100.5M |
7/2016 | Progyny | Series B | 14.7M |
9/2016 | IOmx Therapeutics | Series A | 44.6M |
10/2021 | IOmx Therapeutics | Series B | 0 |
2/2022 | Plexium | Series B | 0 |
2/2021 | Medisafe | Series C | 0 |
6/2023 | Astraveus | Seed Round | 0 |
5/2018 | Akili Interactive Labs | Series C | 0 |
5/2021 | Akili Interactive Labs | Series D | 0 |
10/2022 | Metalenz | Series B | 0 |
1/2023 | Rewind Therapeutics | Series B | - |
5/2019 | Altoida | Series A | 6.3M |
12/2022 | Sonde Health | Series B | 19.3M |
11/2015 | ObsEva | Series B | 58.9M |
11/2019 | ResoTher Pharma | Seed Round | 2.4M |
4/2021 | Anavo Therapeutics | Seed Round | 0 |
2/2018 | FanAI | Seed Round | 2.5M |
3/2013 | Calypso Biotech | Seed Round | 3.3M |
9/2020 | Mosa Meat | Series B | 0 |
8/2017 | Alcan Systems | Series A | 8.8M |
5/2021 | MemryX | Series A | - |
9/2015 | Asceneuron | Series A | 30.8M |
5/2022 | PictorLabs | Series A | 0 |
2/2023 | UNISERS | Seed Round | 14M |
4/2014 | Padlock Therapeutics | Series A | 14.7M |
6/2017 | iOnctura | Seed Round | - |
2/2021 | Metalenz | Series A | 10M |
4/2009 | Ambrx | Series D | 10M |
2/2019 | Calypso Biotech | Series A | 22.7M |
9/2021 | Calypso Biotech | Series A | 0 |
1/2022 | Future Fertility | Series A | - |
10/2017 | Peratech | Equity | 12.4M |
2/2014 | Synaffix BV | Series A | - |
6/2009 | Anaphore | Series A | 13M |
3/2014 | Bird Rock Bio | Series B | 0 |
4/2019 | Sonde Health | Series A | 0 |
1/2020 | iOnctura | Series A | 16.6M |
6/2023 | Celestial AI | Series B | 100M |
1/2012 | Galecto | Seed Round | - |
4/2013 | Canbex Therapeutics | Venture Round | 3.2M |
3/2017 | Medisafe | Series B | 0 |
9/2021 | Legendairy Foods | Series A | 0 |
11/2017 | Wiliot | Series A | 5M |
9/2020 | NanoSyrinx | Pre Seed Round | - |
8/2018 | ApoGen Biotechnologies | Series A | 4M |
1/2017 | ARTSaVIT | Series A | 6.3M |
7/2021 | Wiliot | Series C | 0 |
11/2021 | Biolinq | Series B | 0 |
8/2021 | Immunitas Therapeutics | Series B | 0 |
7/2020 | iOnctura | Series A | 5.8M |
5/2018 | Gamelynx | Equity | 1.2M |
11/2020 | F-Star Therapeutics | Post-IPO Equity | 0 |
8/2018 | Vantage Point | Pre Seed Round | 1.4M |
1/2017 | Macrophage Pharma | Series A | 0 |
10/2018 | Galecto | Series C | 90.2M |
2/2017 | Prexton Therapeutics | Series B | 31.1M |
11/2021 | NeoLogic (VLSI) | Seed Round | 2.8M |
7/2021 | Artios Pharma | Series C | 0 |
3/2022 | Concerto Biosciences | Equity | 24.5M |
7/2020 | DNA Script | Series B | 50M |
6/2017 | Indi Molecular | Series A | 0 |
5/2020 | SynSense | Series A | - |
9/2016 | Artios Pharma | Series A | 0 |
2/2018 | FanAI | Venture Round | 0 |
11/2018 | curbFlow | Seed Round | - |
7/2019 | Forendo Pharma | Venture Round | 0 |
5/2019 | Storm Therapeutics | Series A | 17.8M |
7/2021 | NanoSyrinx | Seed Round | 8.5M |
2/2015 | Prexton Therapeutics | Series A | 10M |
8/2018 | Vantage Point | Pre Seed Round | 0 |
9/2017 | DNA Script | Series A | 13.2M |
11/2020 | Ferroelectric Memory Company | Series B | 0 |
12/2022 | Storm Therapeutics | Series B | 30M |
10/2013 | Galecto | Series B | 6.3M |
3/2022 | Altoida | Series A | 0 |
2/2022 | Plexium | Series B | 0 |
2/2022 | Micropsi Industries | Series B | 0 |
2/2022 | Celestial AI | Series A | 0 |
1/2022 | Future Fertility | Series A | - |
11/2021 | NeoLogic (VLSI) | Seed Round | 0 |
11/2021 | Biolinq | Series B | 0 |
10/2021 | DNA Script | Series C | 0 |
10/2021 | IOmx Therapeutics | Series B | 0 |
9/2021 | Legendairy Foods | Series A | 0 |
Name | Price |
---|
Name | Size | Announced Date |
---|